Replies to post #1169 on Israel-Medical-Healthcare

[genisi]

hey say about 2mg was chosen to go forward an in the one presentation it looks like they tried 1mg and 2mg. Do you know if they had less efficacy at a higher dose?

Yes, the 4mg dose was dropped as efficacy with the 2mg dose was better (better than of 1mg as well). Current trial in RA not using 4mg dose.
ED indication is nothing to look forward to but Eye Indications is. They have another close molecule - CF102 but early.
As I've posted before, I know and appreciate P. Fishman and she is reliable. Another positive is the small market cap like you said and the big opportunity in the target indications. On the other hand, difficult markets to penetrate and no partner so also need to raise cash. The drug seems quite safe but not clear if efficacy is good enough.
Next presentation at JP Morgan this month.